Skip to content
Trial Eligibility
Menu

A Study of LY4355756 in Healthy Participants

NCT07765498

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants. There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Healthy

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 to 65 years
Sex
All
Healthy volunteers
Accepted
Sponsor
Eli Lilly and Company
Last updated on ClinicalTrials.gov
October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Texas · 1

  • Fortrea Clinical Research Unit · Dallas, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.